Sébastien Enault brings to the Company a proven track record in the development of collaborations in the pharmaceutical field and, in particular, in the anti-infective field.
Montpellier, 24 July 2017 (8:30am CEST) – DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, notably from the Deinococcus genus, announces that Sébastien Enault joins the Executive Committee as Business Development Director.
Sébastien Enault, Engineer in Pharmacology and Biotechnologies, has been actively involved in the Business Development of MedinCell, a biopharmaceutical company specializing in long-acting drug delivery. In ten years, he has contributed to the rapid growth of the company, including the signing of partnerships and agreements with major pharmaceutical companies. Recently, he was in charge of the Business Development of Eligo Bioscience, a start-up hosted at the Institut Pasteur in Paris, which develops a new generation of ultra-targeted antibiotics.
Prior to his experience in the private sector, Sébastien conducted research in pharmacology in the fields of infectious diseases, oncology and neurology at the Faculty of Pharmacy in Marseille, then at Cancer Research UK, and at Harvard Medical School.
"We are pleased to welcome Sébastien to expand and promote our portfolio of programs and products in the healthcare and cosmetics markets, two major areas for the Company and in which his experience will be very useful. He will also contribute to the launch, planned next year, of our first cosmetic ingredients," says Emmanuel Petiot, CEO of DEINOVE.
Sébastien Enault adds: "DEINOVE's approach is disruptive, both from the standpoint of the biodiversity of its bank of strains and its integrated technological platform. It offers significant potential for the discovery of new molecules to build a portfolio of products likely to attract pharmaceutical companies."